Head to Head Analysis: Macrocure (MCUR) and AbbVie (ABBV)
Macrocure (NASDAQ: MCUR) and AbbVie (NYSE:ABBV) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.
This is a breakdown of recent recommendations for Macrocure and AbbVie, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
AbbVie has a consensus price target of $90.67, suggesting a potential upside of 1.08%. Given AbbVie’s higher possible upside, analysts plainly believe AbbVie is more favorable than Macrocure.
Risk and Volatility
Macrocure has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500.
Valuation and Earnings
This table compares Macrocure and AbbVie’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|AbbVie||$26.71 billion||5.35||$11.57 billion||$4.07||22.04|
AbbVie has higher revenue and earnings than Macrocure. Macrocure is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.
AbbVie pays an annual dividend of $2.56 per share and has a dividend yield of 2.9%. Macrocure does not pay a dividend. AbbVie pays out 62.9% of its earnings in the form of a dividend. AbbVie has raised its dividend for 44 consecutive years.
This table compares Macrocure and AbbVie’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
2.8% of Macrocure shares are held by institutional investors. Comparatively, 68.3% of AbbVie shares are held by institutional investors. 0.2% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
AbbVie beats Macrocure on 12 of the 13 factors compared between the two stocks.
Macrocure Company Profile
Leap Therapeutics Ltd, formerly Macrocure Ltd, is a biotechnology company. The Company is focused on developing, manufacturing and commercializing cell therapy products to address unmet needs for the treatment of chronic wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Its product candidate, CureXcell, is a combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure. CureXcell is in Phase III. Its CureXcell addresses each phase of healing in the impaired wound, including the production of growth factors and other biochemical factors involved in fibroblast activation, cell migration and extracellular matrix production, stimulating the body’s natural healing process. Its delivery method of direct superficial injection into the chronic wound allows the precise delivery of the cells into the defective wound tissue where they can be effective.
AbbVie Company Profile
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).
Receive News & Stock Ratings for Macrocure Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Macrocure Ltd and related stocks with our FREE daily email newsletter.